Abstract | OBJECTIVE: METHODS: One hundred and six BPH patients were randomly assigned to the treatment group (53 cases) and the control group (53 cases) according to a random number table. The treatment group was given KQR orally; the control group was given cernilton orally. After 24-week treatment, the clinical effect and safety were evaluated using the International Prostatic Symptom Score (I-PSS), quality of life (QOL), maximum flow rate (Qmax), average flow rate (Qave), residual urine volume (RUV), total prostatic volume (TPV), etc. RESULTS:
After treatment, the score of I-PSS was decreased from 16.9±5.6 to 12.5±4.6 in the treatment group, significantly lower compared with the control group; the levels of Qmax and Qave were from 10.9±3.5 to 15.6±4.5 and 5.4±2.1 to 7.3±2.5 (mL/s) in the treatment group, significantly higher compared with the control group; the levels of RUV and TPV were from 70.8±28.2 to 35.2±21.8 and 37.2±16.9 to 30.1±10.8 (mL) in the treatment group, significantly lower compared with the control group (all P<0.05). The incidence rate of adverse reaction was similar between the two groups (P>0.05). CONCLUSION: KQR is effective and safe for the treatment of BPH.
|
Authors | Yuan-peng Huang, Yan-hui Wen, Geng-hui Wu, Zhen-feng Hong, Shang-wen Xu, A-xiang Peng |
Journal | Chinese journal of integrative medicine
(Chin J Integr Med)
Vol. 20
Issue 12
Pg. 949-54
(Dec 2014)
ISSN: 1672-0415 [Print] China |
PMID | 25428342
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Drugs, Chinese Herbal
- kangquan
|
Topics |
- Aged
- Drugs, Chinese Herbal
(adverse effects, therapeutic use)
- Humans
- Male
- Middle Aged
- Organ Size
- Prostate
(pathology)
- Prostatic Hyperplasia
(drug therapy, physiopathology, urine)
- Treatment Outcome
- Urination
|